Toward rapamycin analog (rapalog)-based precision cancer therapy.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Rapamycin analogs (rapalogs) are mTOR inhibitors used in cancer therapy.
• Approved rapalogs like temsirolimus and everolimus treat breast and renal cancers.
• Current objective response rates for rapalogs are modest and variable.

Purpose of the Study:

• To review predictive biomarkers for rapalog efficacy.
• To document recent combination therapies involving rapalogs.
• To highlight the role of PI3K/mTOR pathway aberrations.

Main Methods:

• Review of literature on rapalogs and mTOR inhibitors.
• Focus on PI3K/mTOR pathway aberrations as predictive biomarkers.
• Documentation of clinical trial results for combination therapies.

Main Results:

• PI3K/mTOR pathway aberrations are potential predictive biomarkers for rapalog efficacy.
• Combination therapies with rapalogs show promise for improved efficacy.
• Next-generation sequencing and precision medicine are advancing rapalog applications.

Conclusions:

• Identifying predictive biomarkers is crucial for optimizing rapalog therapy.
• Combination strategies are essential for enhancing rapalog effectiveness.
• Rapalogs hold significant potential for future cancer patient benefits.